阿奇霉素与 SARS-CoV-2 感染：我们现在在哪里，以及我们将走向何方。
Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.
机构信息
Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali 760031, Colombia.
Facultad de Ciencias de la Salud, Universidad Icesi, Calle 18 No. 122-135, Cali 760031, Colombia.
出版信息
J Glob Antimicrob Resist. 2020 Sep;22:680-684. doi: 10.1016/j.jgar.2020.06.016. Epub 2020 Jul 1.
Abstract
• Azithromycin (AZM) is a promising drug candidate for the treatment of the COVID-19. • Studies so far on the use of AZM in COVID-19 patients have various methodological limitations. • The evidence on the efficacy of AZM as an adjunct to hydroxychloroquine for COVID-19 is not enough yet. • Combination of AZM and HCQ should be decided with caution due serious cardiac adverse effects. • Currently, 21 clinical trials are being carried out on the use of AZM in COVID-19.
摘要
• 阿奇霉素（AZM）是治疗 COVID-19 的有前途的候选药物。
• 迄今为止，关于 AZM 在 COVID-19 患者中的使用的研究存在各种方法学局限性。
• 关于 AZM 作为 COVID-19 辅助治疗羟氯喹的疗效的证据还不够充分。
• 由于严重的心脏不良反应，AZM 和 HCQ 的联合使用应谨慎决定。
• 目前，正在进行 21 项关于 AZM 在 COVID-19 中的应用的临床试验。
相似文献
1
Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going.阿奇霉素与 SARS-CoV-2 感染：我们现在在哪里，以及我们将走向何方。
J Glob Antimicrob Resist. 2020 Sep;22:680-684. doi: 10.1016/j.jgar.2020.06.016. Epub 2020 Jul 1.
2
Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19.羟氯喹啉联合阿奇霉素对一组新发COVID-19老年患者体内SARS-CoV-2清除的明显无效性。
Travel Med Infect Dis. 2020 Sep-Oct;37:101826. doi: 10.1016/j.tmaid.2020.101826. Epub 2020 Jul 31.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19.羟氯喹和阿奇霉素作为新型冠状病毒肺炎的一种治疗方法。
Intern Emerg Med. 2020 Aug;15(5):841-843. doi: 10.1007/s11739-020-02388-y. Epub 2020 May 30.
4
Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend.新冠病毒肺炎患者短期使用羟氯喹和阿奇霉素的经验及其对QTc趋势的影响
J Infect. 2020 Aug;81(2):e117-e119. doi: 10.1016/j.jinf.2020.05.058. Epub 2020 May 28.
5
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".没有证据表明用羟氯喹和阿奇霉素对新冠病毒疾病患者进行早期治疗有临床益处：对《用羟氯喹和阿奇霉素对新冠病毒疾病患者进行早期治疗：法国马赛1061例回顾性分析》的评论
Travel Med Infect Dis. 2020 Jul-Aug;36:101819. doi: 10.1016/j.tmaid.2020.101819. Epub 2020 Jul 3.
6
Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center.在新型冠状病毒肺炎疫情背景下羟氯喹及其与阿奇霉素联合使用的安全性：比利时一家三级中心的临床经验
Travel Med Infect Dis. 2020 Jul-Aug;36:101788. doi: 10.1016/j.tmaid.2020.101788. Epub 2020 Jun 12.
7
Hydroxychloroquine-azithromycin for COVID-19 - Warranted or dangerous?用于治疗COVID-19的羟氯喹啉-阿奇霉素——合理还是危险？
Travel Med Infect Dis. 2020 May-Jun;35:101764. doi: 10.1016/j.tmaid.2020.101764. Epub 2020 May 30.
8
Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research.用于治疗新冠病毒病的羟氯喹——当疫情发展速度超过研究速度时
Int J Cardiol. 2020 Oct 1;316:285-286. doi: 10.1016/j.ijcard.2020.05.079. Epub 2020 May 29.
9
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
10
Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.《羟氯喹啉和阿奇霉素治疗新型冠状病毒肺炎：一项开放标签非随机临床试验的结果》综述 Gautret等人，2010年，DOI:10.1016/j.ijantimicag.2020.105949
Int J Antimicrob Agents. 2020 Jul;56(1):106063. doi: 10.1016/j.ijantimicag.2020.106063. Epub 2020 Jul 13.
引用本文的文献
1
A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings.一项关于新冠疫情对资源匮乏地区三级护理教学医院抗生素使用情况及质量影响的回顾性研究
Antibiotics (Basel). 2025 May 23;14(6):535. doi: 10.3390/antibiotics14060535.
2
Is there a correlation between antibiotic use and the severity or post-infection conditions of COVID-19 and other viral infections?抗生素的使用与 COVID-19 和其他病毒感染的严重程度或感染后状况之间是否存在关联？
Clin Exp Med. 2023 Dec;23(8):4123-4128. doi: 10.1007/s10238-023-01171-5. Epub 2023 Aug 31.
3
Azithromycin in patients with COVID-19: a systematic review and meta-analysis.阿奇霉素治疗 COVID-19 患者的疗效：系统评价和荟萃分析。
J Antimicrob Chemother. 2022 Feb 2;77(2):303-309. doi: 10.1093/jac/dkab404.
4
Evaluation of early antibiotic use in patients with non-severe COVID-19 without bacterial infection.评价无细菌感染的轻症 COVID-19 患者的早期抗生素使用情况。
Int J Antimicrob Agents. 2022 Jan;59(1):106462. doi: 10.1016/j.ijantimicag.2021.106462. Epub 2021 Oct 23.
5
COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development.新型冠状病毒肺炎：诊断、治疗进展与疫苗研发
Curr Clin Microbiol Rep. 2021;8(3):152-166. doi: 10.1007/s40588-021-00157-9. Epub 2021 Feb 15.
6
COVID-19, cytokines, inflammation, and spices: How are they related?新型冠状病毒肺炎、细胞因子、炎症与香料：它们之间有何关联？
Life Sci. 2021 Nov 1;284:119201. doi: 10.1016/j.lfs.2021.119201. Epub 2021 Feb 16.
7
Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review).应对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的威胁：现状、挑战与治疗策略（综述）
Exp Ther Med. 2021 Feb;21(2):155. doi: 10.3892/etm.2020.9587. Epub 2020 Dec 17.
8
SARS-CoV-2 Entry Genes Expression in Relation with Interferon Response in Cystic Fibrosis Patients.严重急性呼吸综合征冠状病毒2型进入基因表达与囊性纤维化患者干扰素反应的关系
Microorganisms. 2021 Jan 3;9(1):93. doi: 10.3390/microorganisms9010093.
9
Comprehensive assessment of side effects in COVID-19 drug pipeline from a network perspective.从网络角度全面评估 COVID-19 药物研发管线中的副作用。
Food Chem Toxicol. 2020 Nov;145:111767. doi: 10.1016/j.fct.2020.111767. Epub 2020 Sep 21.
10
The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).血红素加氧酶 1（HMOX1）通路作为 2019 年新型冠状病毒（COVID-19，即 SARS-CoV-2）治疗和预防的有前途靶点。
Int J Mol Sci. 2020 Sep 3;21(17):6412. doi: 10.3390/ijms21176412.
本文引用的文献
1
Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).COVID-19 住院患者使用羟氯喹（无论是否联合使用阿奇霉素）导致 QT 间期延长的风险。
JAMA Cardiol. 2020 Sep 1;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834.
2
Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).急件：针对新型冠状病毒病（COVID-19）可能的药物治疗的 QTc 延长和致扭转型心动过速的潜在风险的应对和规避指导建议。
Mayo Clin Proc. 2020 Jun;95(6):1213-1221. doi: 10.1016/j.mayocp.2020.03.024. Epub 2020 Apr 7.
3
Macrolide treatment for COVID-19: Will this be the way forward?大环内酯类药物治疗 COVID-19：这将是未来的方向吗？
Biosci Trends. 2020 May 21;14(2):159-160. doi: 10.5582/bst.2020.03058. Epub 2020 Apr 5.
4
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
5
COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?2019冠状病毒病与自然衰老：衰老细胞溶解药物及其他抗衰老药物能否用于治疗或预防冠状病毒感染？
Aging (Albany NY). 2020 Mar 30;12(8):6511-6517. doi: 10.18632/aging.103001.
6
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
7
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
8
An eye for azithromycin: review of the literature.阿奇霉素的观察：文献综述
Ther Adv Ophthalmol. 2018 Jul 30;10:2515841418783622. doi: 10.1177/2515841418783622. eCollection 2018 Jan-Dec.
9
Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.阿奇霉素、心血管风险、QTc间期延长、尖端扭转型室速及监管问题：基于病例报告研究的叙述性综述
Ther Adv Infect Dis. 2013 Oct;1(5):155-65. doi: 10.1177/2049936113501816.
10
Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells.阿奇霉素在 LPS 刺激的 J774A.1 细胞中的抗炎作用机制。
Pharmacol Res. 2012 Oct;66(4):357-62. doi: 10.1016/j.phrs.2012.06.011. Epub 2012 Jul 3.
Zotero 插件